Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

G. Bonadonna, P. Valagussa, A. Rossi, G. Tancini, C. Brambilla, M. Zambetti, U. Veronesi

Research output: Contribution to journalArticlepeer-review


The paper reviews all adjuvant studies carried out since 1973 at the Milan Cancer Institute in women with resectable breast cancer and positive axillary nodes. The updated results essentially confirm previous findings, and indicate that CMF-based chemotherapy is able to exert a prolonged therapeutic activity in a fraction of patients bearing micrometastases. In particular, the first randomized study testing no postoperative chemotherapy vs 12 CMF cycles, showed a 10-year relapse free survival (RFS) of 31.4% vs 43.4% (P

Original languageEnglish
Pages (from-to)95-115
Number of pages21
JournalBreast Cancer Research and Treatment
Issue number2
Publication statusPublished - Jun 1985


  • adjuvant treatment
  • breast cancer
  • chemotherapy
  • CMF program

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer'. Together they form a unique fingerprint.

Cite this